Journey Medical (DERM) Q1 2026 earnings review
Emrosi Growth Continues, But Operating Leverage Narrative Cracks
Journey Medical posted 21% YoY revenue growth, fueled entirely by the Emrosi launch ($6.3M). The headline numbers look solid: Adjusted EBITDA stayed positive at $0.6M, and the cash balance swelled to $27.2M. However, peeling back the YoY comparisons reveals a concerning sequential trend. Adjusted EBITDA plunged from an estimated $2.6M in Q4 to just $0.6M in Q1, and Net Loss widened. Compounding the margin pressure was a $1.3M API inventory write-down for legacy product Qbrexza. Emrosi's volume and ~85% payer access are clear wins, but the base business decay and stalling sequential margins demand investor caution.
🐂 Bull Case
Payer access expanded to ~85% of commercial lives with a new top-tier GPO contract. Prescription volume accelerated to nearly 30,000 in Q1, proving market demand.
Cash reserves jumped to $27.2M, a $3.1M sequential increase despite accounting net losses, showcasing excellent working capital conversion.
🐻 Bear Case
Management highlighted 'improved operating leverage,' but Adjusted EBITDA collapsed sequentially from an estimated $2.6M in Q4 to $0.6M in Q1.
Qbrexza suffered a $1.3M API inventory write-down, and the base business ex-Emrosi shrank roughly 12% YoY ($11.0M to $9.7M).
⚖️ Verdict: ⚪
Neutral. Emrosi is executing flawlessly on volume and market access, saving the top line. But until the legacy business bottoms out and sequential margin expansion resumes, it's hard to turn fully bullish.
Key Themes
Emrosi TRx Momentum Remains Strong
The core growth engine continues to fire. Emrosi scripts hit 29,968 in Q1, a steady acceleration from 27,023 in Q4. The market is clearly responding to the drug's modified-release technology and superior clinical profile versus the legacy standard of care. With ~85% of commercial lives now covered following a new GPO contract, the friction to fill scripts is rapidly disappearing.
The Operating Leverage Contradiction
CEO Claude Maraoui pointed to 'improved operating leverage' as a highlight of the quarter. While true on a YoY basis, the sequential reality contradicts the positive narrative. Adjusted EBITDA dropped from an estimated $2.6M in 25Q4 to $0.6M in 26Q1, and the net loss expanded from $1.2M to $2.2M. With revenue flat sequentially ($16.1M to $16.0M), the leverage engine has hit a speed bump.
Legacy Portfolio Cracks: Qbrexza Write-Down
Gross margin decelerated to 61.0% from 63.5% a year ago, dragged down by a $1.3M non-cash write-down of active pharmaceutical ingredient (API) inventory for Qbrexza. Excluding this charge, margins would have been a healthy ~69%. However, the write-down itself raises red flags about softening demand or poor inventory forecasting for the base business, which is actively shrinking.
SG&A Discipline Holding Firm
Despite a 21% jump in total revenue and the aggressive ongoing commercialization of Emrosi, SG&A actually declined YoY from $10.6M to $10.1M. This confirms that the heavy lifting of building the dermatology sales infrastructure is complete, and any future gross margin dollars from Emrosi should flow directly to the bottom line.
Other KPIs
A standout metric. Cash grew by $3.1M sequentially despite a $2.2M GAAP net loss. This indicates strong working capital mechanics—likely the collection of strong Q4 receivables—and substantially de-risks the balance sheet while the company navigates the tail-end of its cash-burn phase.
Guidance
Stable. Management declined to provide specific revenue or earnings ranges, only stating they expect 'improved operating leverage' to continue. Given the sequential drop in Adjusted EBITDA from Q4 to Q1, the lack of explicit forward-looking targets leaves investors with limited visibility.
Key Questions
Sequential EBITDA Deterioration
Why did Adjusted EBITDA and Net Income deteriorate sequentially from Q4 to Q1 despite continued Emrosi script growth and stable SG&A?
Qbrexza Demand
Does the $1.3M Qbrexza API write-down signal a permanent impairment in the demand forecast for that franchise, or was this strictly an expiration timing issue?
Gross-to-Net Normalization
With approximately 85% of commercial lives now covered following the latest GPO contract, at what specific timeframe do you expect the gross-to-net margin to fully normalize?